glp-1 obesity drug news today oct 23 2025 GLP-1 Drugs: 2025 Pulse Survey (U.S.)-mvanhaasteren.nl ADA '26: Lilly's dominance, Pfizer's

Read the FDAs full warning here: #GLP1 #ClinicalTrials #PatientSafety #AccessEquity #ObesityResearch #DecentralizedTrials

No injections

This interaction triggers multiple beneficial effects, such as enhancing insulin release from the pancreas when glucose levels are high, suppressing glucagon (which raises blood sugar), and signaling the brain to promote fullness

In recent years, GLP-1 medications have gained attention for their role in managing weight and supporting metabolic health

Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes